AZN vs. NVAX

Last updated Apr 2, 2026

Compare and contrast key facts about AstraZeneca PLC (AZN) and Novavax, Inc. (NVAX).

Performance

AZN vs. NVAX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AstraZeneca PLC (AZN) and Novavax, Inc. (NVAX). The values are adjusted to include any dividend payments, if applicable.

AZN vs. NVAX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AZN AstraZeneca PLC	11.46%	43.30%	-0.62%	1.44%	19.14%	19.66%	3.12%	35.68%	13.86%	33.10%
NVAX Novavax, Inc.	19.35%	-16.42%	67.50%	-53.31%	-92.81%	28.30%	2,701.76%	-89.18%	48.39%	-1.59%

Fundamentals

Market Cap AZN : $313.54B NVAX : $1.39B
EPS AZN : $6.55 NVAX : $2.58
PE Ratio AZN : 30.64 NVAX : 3.11
PS Ratio AZN : 5.33 NVAX : 1.22
Total Revenue (TTM) AZN : $58.74B NVAX : $1.12B
Gross Profit (TTM) AZN : $48.11B NVAX : $1.05B
EBITDA (TTM) AZN : $19.83B NVAX : $452.80M

Returns By Period

In the year-to-date period, AZN achieves a 11.46% return, which is significantly lower than NVAX's 19.35% return. Over the past 10 years, AZN has outperformed NVAX with an annualized return of 16.92%, while NVAX has yielded a comparatively lower -23.02% annualized return.

AZN

• 1D: 1.78%
• 1M: -1.47%
• YTD: 11.46%
• 6M: 21.46%
• 1Y: 42.12%
• 3Y*: 15.74%
• 5Y*: 17.86%
• 10Y*: 16.92%

NVAX

• 1D: -1.47%
• 1M: -20.67%
• YTD: 19.35%
• 6M: -15.58%
• 1Y: 33.67%
• 3Y*: 4.99%
• 5Y*: -46.66%
• 10Y*: -23.02%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AZN vs. NVAX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AZN

AZN Risk / Return Rank: 84
AZN Sharpe Ratio Rank: 85
AZN Sortino Ratio Rank: 82
AZN Omega Ratio Rank: 80
AZN Calmar Ratio Rank: 87
AZN Martin Ratio Rank: 85

NVAX

NVAX Risk / Return Rank: 57
NVAX Sharpe Ratio Rank: 56
NVAX Sortino Ratio Rank: 61
NVAX Omega Ratio Rank: 57
NVAX Calmar Ratio Rank: 57
NVAX Martin Ratio Rank: 56

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AZN vs. NVAX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Novavax, Inc. (NVAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AZN	NVAX	Difference
Sharpe ratio Return per unit of total volatility	1.56	0.44	+1.11
Sortino ratio Return per unit of downside risk	2.25	1.24	+1.01
Omega ratio Gain probability vs. loss probability	1.29	1.14	+0.15
Calmar ratio Return relative to maximum drawdown	3.25	0.70	+2.55
Martin ratio Return relative to average drawdown	8.16	1.48	+6.68
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AZN vs. NVAX - Sharpe Ratio Comparison

The current AZN Sharpe Ratio is 1.56, which is higher than the NVAX Sharpe Ratio of 0.44. The chart below compares the historical Sharpe Ratios of AZN and NVAX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AZN	NVAX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.56	0.44	+1.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.75	-0.44	+1.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.68	-0.20	+0.88
Sharpe Ratio (All Time) Calculated using the full available price history	0.51	-0.07	+0.58

Correlation

The correlation between AZN and NVAX is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AZN vs. NVAX - Dividend Comparison

AZN's dividend yield for the trailing twelve months is around 2.65%, while NVAX has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
AZN AstraZeneca PLC	2.65%	1.70%	2.27%	2.15%	2.12%	2.35%	2.80%	2.81%	3.69%	3.95%	5.01%	4.06%
NVAX Novavax, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

AZN vs. NVAX - Drawdown Comparison

The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum NVAX drawdown of -98.82%. Use the drawdown chart below to compare losses from any high point for AZN and NVAX.

Drawdown Indicators

	AZN	NVAX	Difference
Max Drawdown Largest peak-to-trough decline	-48.94%	-98.82%	+49.88%
Max Drawdown (1Y) Largest decline over 1 year	-12.24%	-35.94%	+23.70%
Max Drawdown (5Y) Largest decline over 5 years	-27.87%	-98.61%	+70.74%
Max Drawdown (10Y) Largest decline over 10 years	-27.87%	-98.82%	+70.95%
Current Drawdown Current decline from peak	-3.70%	-97.49%	+93.79%
Average Drawdown Average peak-to-trough decline	-11.38%	-70.56%	+59.18%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.88%	16.94%	-12.06%

Volatility

AZN vs. NVAX - Volatility Comparison

The current volatility for AstraZeneca PLC (AZN) is 7.15%, while Novavax, Inc. (NVAX) has a volatility of 15.78%. This indicates that AZN experiences smaller price fluctuations and is considered to be less risky than NVAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AZN	NVAX	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.15%	15.78%	-8.63%
Volatility (6M) Calculated over the trailing 6-month period	19.20%	47.46%	-28.26%
Volatility (1Y) Calculated over the trailing 1-year period	27.33%	76.52%	-49.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.85%	107.05%	-83.20%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	24.90%	115.25%	-90.35%

Financials

AZN vs. NVAX - Profitability Comparison

The chart below illustrates the profitability comparison between AstraZeneca PLC and Novavax, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported a gross profit of 12.39B and revenue of 15.50B. Therefore, the gross margin over that period was 79.9%.

NVAX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novavax, Inc. reported a gross profit of 123.94M and revenue of 147.14M. Therefore, the gross margin over that period was 84.2%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported an operating income of 2.98B and revenue of 15.50B, resulting in an operating margin of 19.2%.

NVAX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novavax, Inc. reported an operating income of 9.63M and revenue of 147.14M, resulting in an operating margin of 6.5%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported a net income of 2.33B and revenue of 15.50B, resulting in a net margin of 15.0%.

NVAX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novavax, Inc. reported a net income of 17.53M and revenue of 147.14M, resulting in a net margin of 11.9%.